0000899243-23-015998.txt : 20230620 0000899243-23-015998.hdr.sgml : 20230620 20230620172301 ACCESSION NUMBER: 0000899243-23-015998 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230615 FILED AS OF DATE: 20230620 DATE AS OF CHANGE: 20230620 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Meisner Lara CENTRAL INDEX KEY: 0001883986 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36483 FILM NUMBER: 231026440 MAIL ADDRESS: STREET 1: C/O VIRIDIAN THERAPEUTICS, INC. STREET 2: 203 CRESCENT STREET, BLDG. 17, SUITE 102 CITY: WALTHAM STATE: MA ZIP: 02453 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viridian Therapeutics, Inc.\DE CENTRAL INDEX KEY: 0001590750 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 471187261 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 203 CRESCENT STREET STREET 2: BLDG. 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 617.272.4600 MAIL ADDRESS: STREET 1: 203 CRESCENT STREET STREET 2: BLDG. 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC. DATE OF NAME CHANGE: 20170213 FORMER COMPANY: FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC. DATE OF NAME CHANGE: 20170213 FORMER COMPANY: FORMER CONFORMED NAME: SIGNAL GENETICS, INC. DATE OF NAME CHANGE: 20140710 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-15 0 0001590750 Viridian Therapeutics, Inc.\DE VRDN 0001883986 Meisner Lara C/O VIRIDIAN THERAPEUTICS, INC. 221 CRESCENT STREET, SUITE 401 WALTHAM MA 02453 0 1 0 0 Chief Legal Officer 0 Common Stock 2023-06-15 4 M 0 2269 23.03 A 32240 D Common Stock 2023-06-15 4 S 0 2269 28.02 D 29971 D Common Stock 2023-06-16 4 M 0 27 23.03 A 29998 D Common Stock 2023-06-16 4 S 0 27 28.35 D 29971 D Stock Option (Right to Buy) 23.03 2023-06-15 4 M 0 2269 0.00 D 2031-01-18 Common Stock 2269 37481 D Stock Option (Right to Buy) 23.03 2023-06-16 4 M 0 28 0.00 D 2031-01-18 Common Stock 28 37453 D This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 7, 2023 (the "Plan") in multiple trades at prices ranging from $28.00 to $28.09. The price reported above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed pursuant to the Plan. The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. /s/ Kristian Humer, Attorney-in-Fact for Lara Meisner 2023-06-20